N-propargylglycine restores survival by preventing calcium oxalate stone formation, tubular injury, and kidney dysfunction in a lethal mouse model of primary hyperoxaluria type 2

In mice bred to die of kidney failure by 15 weeks, a daily pill restored normal survival and stopped stone formation entirely

Journal: Kidney International | Published: 2026-03-20 | Type: Journal Article | PMID: 41866121 Authors: Hady M, Tadeo A, Stoyanova D, Scott GK, Baker HL, Wilson KA, Ingle H, Ashok Kumaar PV, Ambrose BD, Schilling B (all Buck Institute for Research on Aging, Novato, CA) Funding/COI: NINDS and NIA (NIH); no COI disclosed

Summary

Researchers gave a small-molecule drug called N-propargylglycine (N-PPG) to mice genetically engineered to develop primary hyperoxaluria type 2 (PH2), a rare and often fatal kidney stone disease. Untreated mice died young, with a median survival of just 15 weeks. Mice given N-PPG survived and gained weight at the same rate as healthy control mice, with no kidney stones and no measurable kidney damage.

Claims

• Vehicle-treated Grhpr knockout mice (the PH2 model) had a median survival of 15 weeks
• Daily oral N-PPG restored survival and body weight in these mice to levels matching wild-type controls over a 24-week study
• N-PPG reduced hyperoxaluria and weight loss within three weeks of starting treatment
• Treated mice showed no calcium oxalate stone formation and no kidney tubular injury, measured via kidney injury molecule-1 and Lotus Tetragonolobus lectin staining
• Kidney function markers (Cystatin C, albumin/creatinine ratio) remained normal in treated mice throughout the study
• N-PPG works by inhibiting Hypdh/Prodh2, a mitochondrial liver and kidney enzyme upstream of oxalate production

Study Quality

This is a mouse study using the Grhpr knockout model, which recapitulates PH2 pathophysiology through an accelerated, severe disease course. The design includes three groups implied by the results (vehicle-treated knockouts, N-PPG-treated knockouts, wild-type controls), and the primary endpoint is survival over 24 weeks, a hard outcome rather than a surrogate marker. That's a meaningfully stronger endpoint than most preclinical pharmacology papers use. The abstract doesn't report group sizes (n per arm), so it's impossible to judge statistical power from what's given here.

The work comes from a single institution, the Buck Institute for Research on Aging, which is notable: it's a basic aging-biology lab, not a nephrology center, publishing in Kidney International. That's not disqualifying, but it's worth knowing the group's primary expertise is metabolism and aging pathways rather than clinical nephrology.

Red Flags

• Mouse-only data; no human pharmacokinetics, dosing, or safety data reported
• Sample sizes per group not stated in the abstract
• Single genetic model (Grhpr KO for PH2); results may not extend to PH1, the most common and severe form, or PH3
• Single-center study, no independent replication
• Funding is from NINDS and NIA, both somewhat unusual sources for a kidney stone disease drug, more typical would be NIDDK, though this likely reflects the Buck Institute's aging-research funding base rather than a red flag about the science itself

Strengths

• Uses survival as the primary endpoint, not a surrogate biomarker
• 24-week treatment duration, long enough to demonstrate durability rather than a short-term rescue effect
• Combines biochemical (oxalate, Cystatin C, albumin/creatinine ratio), histological (KIM-1, lectin staining), and metabolomic readouts, which corroborate each other rather than relying on one measure
• Targets a real unmet need: PH2 currently has no approved disease-modifying therapy, unlike PH1, which has RNAi drugs on the market
• Mechanistically plausible target (Hypdh/Prodh2 inhibition upstream of oxalate synthesis), consistent with prior genetic knockout data cited in the introduction

Verdict

Solid, mechanistically coherent preclinical pharmacology with a genuinely hard endpoint, full survival rescue in a disease model that's normally fatal by 15 weeks is a real result, not a marginal biomarker shift. But this is one mouse model, one lab, and zero human data. PH2 patients and their families should treat this as an early signal worth tracking into human trials, not as a treatment on the horizon yet.